25N-NBOMe
4-nitro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
25N-NBOMe — called an N-bomb — is a synthetic psychedelic of the NBOMe series. It is the nitro-substituted member of the series, built on the 2C-N scaffold. It activates serotonin receptors in the brain with full force, producing intense visual and cognitive distortion.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, 2C-x compounds, other NBOMe compounds show less
Ralf Heim developed the compound in 2003 as a brain-imaging research tool, not for recreation.[2] It reached drug markets around 2010, routinely sold on blotter paper as LSD — the NBOMe series produced over 50 severe intoxication cases and at least 9 deaths.[3][2] 25N-NBOMe remains one of the least-distributed analogs, controlled in most countries under blanket psychoactive substance laws.
Subjective effects include geometric visual patterns, time alteration, physical stimulation, and anxiety. The experience has a pronounced anxious edge — harsher and more visually overwhelming than classical psychedelics, with a steep intensity curve where small dose changes can shift a trip from manageable to frightening. Thought loops, paranoia, and sensory overload are common unwanted effects.
25N-NBOMe produces no physical dependence, but the NBOMe class carries severe acute toxicity — seizures, organ failure, and cardiovascular collapse have caused multiple deaths.[4] The dose-response curve is steep, compressing the margin between a manageable dose and a medical emergency into an unpredictable sliver. No clinical studies exist on this compound; understanding rests on class pharmacology, lab data, and community reports.
History[edit]
Discovery
2C-N, the parent compound, was synthesized and self-tested by Alexander Shulgin and documented in PiHKAL (1991).[5] In 2003, Ralf Heim's doctoral thesis added an N-(2-methoxybenzyl) group to 2C compounds, dramatically increasing their affinity for serotonin receptors — designed for brain-imaging research.[2] This structural addition made the NBOMe series active at microgram doses.
Designer drug emergence
The NBOMe series reached online drug markets around 2010, sold on blotter paper and frequently misrepresented as LSD.[2] 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe dominated distribution; 25N-NBOMe circulated in smaller volumes. More than 50 severe intoxication cases and at least 9 deaths accumulated across the series.[3][2]
Prohibition
Russia controlled the series in 2011, Sweden in 2013, and the United States permanently scheduled 25I-, 25C-, and 25B-NBOMe in October 2016.[6] 25N-NBOMe was not individually named but is likely covered by the Federal Analogue Act. Brazil explicitly listed 25N-NBOMe in 2014, and the UK's Psychoactive Substances Act 2016 provides blanket coverage.[7]
The name "NBOMe" comes from the compound's defining structural feature: the N-2-methoxybenzyl group. Within drug culture, NBOMe compounds are called "N-bombs" — a name that acquired darker meaning as fatality reports accumulated. The series carries a strongly negative reputation among psychedelic users; "NBOMe" became shorthand for the dangers of unregulated psychedelic markets.
Chemistry[edit]
Structural class
25N-NBOMe belongs to the 25X-NBOMe series of substituted phenethylamines. The class shares a phenethylamine backbone with methoxy groups at the 2- and 5-positions and an N-(2-methoxybenzyl) group — the structural addition that converts low-potency 2C compounds into potent serotonin-receptor agonists.[3] The parent compound is 2C-N.[5]
Molecular identity
The 4-nitro group (–NO₂) at position 4 is unique within the NBOMe series — every other member carries a halogen, methyl, or ethyl group at that position.[8] This group affects how the body breaks the molecule down: enzymes reduce it to a primary aromatic amine, giving 25N-NBOMe distinctive metabolic behavior. The molecular formula is C₁₈H₂₂N₂O₅ (346.4 g/mol).
Pharmacology[edit]
Mechanism of action
25N-NBOMe produces its psychedelic effects by fully activating serotonin receptors.[3] Unlike the parent 2C compounds, which activate them only partially, full agonism means stronger downstream signaling at the same level of receptor occupancy.[1] In animal models, blocking this single receptor type completely eliminates the behavioral effects, confirming it as the essential driver.[9]
The compound's high potency comes from the N-2-methoxybenzyl group, which strengthens its hold on serotonin receptors while leaving most other receptor types unaffected.[3][10] Cardiovascular adverse effects across the NBOMe class — tachycardia, elevated blood pressure, overheating — likely involve serotonin receptor activation plus possible effects on epinephrine receptors.[11]inferred
Pharmacokinetics
No human pharmacokinetic studies have been published for 25N-NBOMe. NBOMe compounds are poorly absorbed when swallowed — stomach degradation and liver metabolism destroy much of the dose.[2] Sublingual administration bypasses this barrier; insufflation produces faster onset and higher peak concentrations, substantially raising overdose risk.[3]
Neuroscience[edit]
Where it acts
25N-NBOMe acts primarily on neurons in the prefrontal cortex — the brain region governing reasoning, perception, and sense of self.[1] Activating these cells increases glutamate release, disrupts the brain's default mode network, and weakens the filtering of sensory information reaching awareness. The result is heightened perceptual complexity: vivid visuals, altered thinking, and a loosened sense of self.
Frameworks and plasticity
NBOMe compounds notably lack activity at a serotonin receptor subtype that classical psychedelics like LSD stimulate.[10] That receptor is thought to buffer anxiety, and its absence may explain why NBOMe experiences are consistently reported as more anxious and less forgiving.
Laboratory studies show that NBOMe compounds damage energy-producing structures inside nerve cells.[12] Whether this translates to lasting harm at recreational doses in humans remains unknown.
No neuroimaging studies of 25N-NBOMe exist. Key unknowns include whether the compound promotes neuroplasticity, whether its unique nitro-group metabolites carry neurotoxic risk, and whether the absence of that anxiety-buffering receptor activity is the mechanistic driver of its anxiogenic profile.
Subjective Effects[edit]
25N-NBOMe delivers an experience defined by intense visual distortion, physical stimulation, and a persistent undercurrent of anxiety. The steep dose-response curve leaves little margin between an interesting trip and an overwhelming one — set and setting carry unusually high weight because the pharmacology offers little internal buffer against difficult emotions.
Compared to LSD, 25N-NBOMe shares similar serotonin-receptor potency but lacks the broader receptor activity that softens LSD's character. Relative to psilocybin, reports describe a more visually driven, more stimulating, and more anxiety-prone experience — though these comparisons rest on user reports rather than controlled studies.
Effect Grid
Full psychedelic effects manifest — prominent color enhancement, visual drifting, geometric patterning, and object transformations. Internal hallucinations become possible. Emotional enhancement intensifies, and time alteration is pronounced. Thought connectivity and conceptual thinking deepen.
Physical load increases: stimulation is prominent, muscle tension and vasoconstriction may cause discomfort, nausea is common, and abnormal heartbeat becomes apparent. Wakefulness and appetite suppression are reliable. Anxiety can become a significant feature of the experience.
The steep dose-response means the upper range of this tier approaches strong-level intensity. Precise dosing and a supportive setting are strongly advised.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Music enhancement · Symmetrical texture repetition · After-images · Brightness alteration · Color alteration · Tracers · Visual morphing · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Spatial disorientation · Visual haze / noise · Visual melting · Touch enhancement · Visual acuity enhancement · Auditory misinterpretation · Holotropic state · Peripheral misidentification · Proprioceptive distortion · Sound sensitivity · Vestibular distortion · Visual diffraction · Taste enhancement · Visual processing acceleration · Synesthesia · Visual magnification · Touch suppression · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · Environmental orbism / cubism · External hallucinations · Object activation · Visual scenery slicing · Auditory hallucinations · Perspective hallucinations · Visual flipping · Gustatory hallucination · Persisting hallucinations
Brightness alteration · Color alteration · Tracers · Visual morphing · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Spatial disorientation · Visual haze / noise · Visual melting · Touch enhancement · Visual acuity enhancement · Auditory misinterpretation · Holotropic state · Peripheral misidentification · Proprioceptive distortion · Sound sensitivity · Vestibular distortion · Visual diffraction · Taste enhancement · Visual processing acceleration · Synesthesia · Visual magnification · Touch suppression · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · Environmental orbism / cubism · External hallucinations · Object activation · Visual scenery slicing · Auditory hallucinations · Perspective hallucinations · Visual flipping · Gustatory hallucination · Persisting hallucinations
Spontaneous body sensations · Muscle tension · Nausea · Appetite suppression · Dry mouth · Body high · Heart rate perception changes · Restlessness · Excessive sweating · Insomnia · Physical fatigue · Tingling / electric sensations · Bodily lightness · Dehydration sensation · Headache · Body schema distortion · Breathing alteration · Dizziness · Laughter fits · Nystagmus (eye wobbles) · Salivation · Tactile euphoria · Trembling · Vibrations / buzzing · Bodily pressures · Bruxism · Involuntary body movements · Respiratory stimulation · Increased urination · Sexual arousal enhancement · Vomiting · Nasal congestion · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Appetite suppression · Dry mouth · Body high · Heart rate perception changes · Restlessness · Excessive sweating · Insomnia · Physical fatigue · Tingling / electric sensations · Bodily lightness · Dehydration sensation · Headache · Body schema distortion · Breathing alteration · Dizziness · Laughter fits · Nystagmus (eye wobbles) · Salivation · Tactile euphoria · Trembling · Vibrations / buzzing · Bodily pressures · Bruxism · Involuntary body movements · Respiratory stimulation · Increased urination · Sexual arousal enhancement · Vomiting · Nasal congestion · Bodily dissociation · Tactile hallucination
Thought acceleration · Immersion enhancement · Conceptual thinking · Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Thought loops · Memory suppression · Cognitive fatigue · Confusion · Creativity enhancement · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Increased nature relatedness · Humor enhancement · Analysis enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Synchronicity · Delusions · Amnesia · Delirium
Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Thought loops · Memory suppression · Cognitive fatigue · Confusion · Creativity enhancement · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Increased nature relatedness · Humor enhancement · Analysis enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Synchronicity · Amnesia · Delirium
Simultaneous emotions · Empathy enhancement · Catharsis · Dysphoria · Irritability
Irritability
Communication suppression · Social disconnection · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Transpersonal feelings · Non-dual awareness
Timeline
Gradual emergence of body awareness and sublingual numbing characteristic of the NBOMe class. Mild stimulation and slight pupil dilation begin.
Rapid escalation of visual and somatic effects. Color enhancement and surface texturing become apparent. Anxiety may intensify during this phase.
Full expression of visual, cognitive, and emotional effects. Maximum sympathomimetic load — tachycardia, muscle tension, and stimulation are most pronounced.
Gradual reduction in visual intensity; stimulation persists. Residual anxiety and muscle tension are common. Cognitive effects slowly clear.
Residual stimulation, possible insomnia, mild cognitive fatigue, and physical recovery. Mood may be flat or mildly dysphoric.
⚠ Do not drive or operate heavy machinery for at least 16 hours after sublingual administration — residual stimulation and cognitive impairment may persist beyond subjective resolution of primary effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
The NBOMe class has caused over 50 severe intoxication cases and at least 9 deaths.[3][2] Severe intoxication presents with violent agitation, seizures, dangerously high body temperature, rapid heart rate, muscle breakdown, and kidney failure — progressing in the worst cases to multi-organ failure and coma.[4][13]
No lethal dose has been established for any species. The dose-response curve is steep: small increases produce disproportionate escalation in both desired and dangerous effects. Dose ranges from community consensus — threshold ~100 µg, light 100–300 µg, common 300–800 µg, strong 800–1,300 µg (sublingual) — have not been verified clinically.safety citation needed
Cardiovascular toxicity
Related NBOMe compounds prolong the heart's electrical recovery interval in rat studies — a disruption that can trigger fatal arrhythmias.[2] Whether 25N-NBOMe shares this property is untested, but the shared pharmacology makes it plausible.
Neurotoxicity
Laboratory studies show NBOMe compounds are more toxic to brain cells than their 2C precursors.[12] Damage involves disrupted energy production and depleted antioxidant defenses in nerve cell models. Whether these findings translate to harm at recreational doses in humans is unknown.
Psychological risks
Acute psychological risks include severe anxiety, panic, paranoia, confusion, and violent agitation.[4][13] The steep dose-response curve increases the chance of overwhelming experiences at doses only slightly above the intended range.
Persistent visual disturbances after use — a condition called HPPD (HPPD) — are a recognized class-level risk.[14] Psychosis is a risk for those with predisposing conditions. No prevalence data specific to 25N-NBOMe exist for either.
Tolerance and dependence
Tolerance develops rapidly after a single dose — serotonin receptors temporarily downregulate after activation. Community sources report near-complete tolerance immediately after use, recovering over roughly 7 days.safety citation needed
Cross-tolerance extends to LSD, psilocybin, mescaline, and 2C compounds via the shared serotonin receptor mechanism. No physical dependence or withdrawal has been reported.
Drug interactions
No interaction studies specific to 25N-NBOMe have been published. The following are based on the compound's pharmacological profile.
Serotonergic agents (MAOIs, SSRIs, SNRIs, tramadol): Combining 25N-NBOMe with other serotonin-raising drugs can trigger serotonin syndrome — a potentially fatal state involving unstable heart rate, blood pressure, temperature, and mental state.[15] This combination is documented in the NBOMe class.
Tramadol carries dual risk: serotonin syndrome hazard plus seizure threshold-lowering, compounding the NBOMe class's intrinsic seizure risk.
Stimulants (cocaine, amphetamines): Combined increases in heart rate, blood pressure, and body temperature produce additive cardiovascular strain — raising the risk of heart rhythm disturbance, seizure, and cardiovascular crisis.
CYP2C9/CYP2C19 inhibitors (fluconazole, fluvoxamine, omeprazole): Based on metabolism data from 25I-NBOMe,[16] these medications could slow 25N-NBOMe clearance, increasing exposure and toxicity risk.
Contraindications
No substance-specific contraindication data exist for 25N-NBOMe. The following are class-level contraindications based on the pharmacology of potent serotonin-activating compounds with cardiovascular stimulant effects.
Heart conditions — High blood pressure, irregular rhythm, and prior cardiac events. NBOMe compounds strain the cardiovascular system and may disrupt heart electrical intervals, creating risk of acute failure.
Seizure disorders — Seizures are documented across multiple NBOMe intoxication cases.[4][13] Pre-existing seizure disorders substantially increase this risk.
Psychiatric conditions — Psychotic spectrum disorders, bipolar disorder, and conditions involving impaired reality testing. Potent serotonin receptor activation can trigger psychosis and psychiatric crisis.
Concurrent serotonergic medication — MAOIs, SSRIs, SNRIs, and tramadol are contraindicated due to serotonin syndrome risk.[15]
Concurrent stimulant use — Cocaine, amphetamines, and other stimulants produce additive cardiovascular strain.
Harm Reduction[edit]
Forms & Identification
25N-NBOMe is almost always distributed on blotter paper — the same format as LSD. Reagent testing is essential: the Ehrlich reagent reacts with LSD but not with phenethylamines, providing a critical first-pass distinction. Reagent testing alone cannot identify 25N-NBOMe specifically among NBOMe analogs.
Powder forms carry additional hazard: the microgram-active dose range means small measurement errors can produce dangerous overdoses. Volumetric dosing from a known-concentration solution is the only reliable approach for powder.
Guidelines
- Test all material with reagent kits before use to distinguish NBOMe compounds from LSD
- Start with the lowest reported threshold dose (~100 µg sublingual) and do not redose
- Use only sublingual administration — insufflation dramatically increases overdose risk[3]
- Ensure a sober, trusted sitter is present throughout the experience
- Choose a safe, comfortable, familiar environment with access to water and temperature control
- Avoid physical exertion, which compounds cardiovascular strain
- Allow a minimum of 7 days between uses for tolerance to reset
- Avoid use with pre-existing heart conditions, seizure disorders, or psychiatric conditions
Set & Setting
25N-NBOMe's pronounced anxiety-inducing character makes psychological preparation and environment unusually important. Unlike LSD, NBOMe compounds lack the receptor activity thought to buffer anxiety — the pharmacology provides little internal cushion against difficult experiences.
A calm, familiar environment with a trusted, sober companion reduces the probability of anxiety escalating. The steep dose-response curve means an overwhelming experience cannot easily be modulated once underway.
Aftercare & integration. The anxiogenic quality of 25N-NBOMe means difficult experiences are common even at moderate doses. After acute effects subside, allow 24–48 hours of low-demand rest. Sleep disruption is typical; avoid stimulants and screens in the hours following offset.
If the experience was distressing, journaling within the first few days can help process difficult material. Persistent anxiety, visual disturbances, or intrusive thoughts lasting beyond one week should prompt consultation with a mental health professional.
Recovery & Support
Compulsive use patterns are rare with serotonergic psychedelics due to rapid tolerance buildup. If repeated use is causing distress or escalating risk-taking, professional support is warranted. Psychedelic-informed therapists, peer support communities, and services like the Fireside Project (62-FIRESIDE / 623-473-7433) offer non-judgmental assistance for people processing difficult psychedelic experiences or seeking to change their relationship with use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Seizures or uncontrollable muscle jerking
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Complete loss of contact with reality, self-harm behavior, or violent agitation
- Loss of consciousness or unresponsiveness
- Dark or absent urine (sign of muscle breakdown and kidney damage)
Immediate steps:
- 1. Call emergency services immediately if any of the above are present
- 2. Move the person to a cool, quiet space
- 3. If conscious, offer small sips of water
- 4. If unconscious and breathing, place in the recovery position (on their side)
- 5. Do not restrain unless there is immediate danger of self-harm or harm to others
- 6. Do not induce vomiting
- 7. Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (25N-NBOMe or "an NBOMe compound"), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Legal Status[edit]
25N-NBOMe is individually named in only a few national frameworks. In most countries, blanket psychoactive substance legislation or structural analog provisions apply because the three most-distributed analogs — 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe — are explicitly controlled.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled (Federal Analogue Act applies) | 25I-, 25C-, and 25B-NBOMe permanently placed in Schedule I (October 2016).[6] 25N-NBOMe not individually named but likely covered under the Federal Analogue Act when intended for human consumption. |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Blanket prohibition on production, supply, and import of psychoactive substances. 25I-NBOMe and 25C-NBOMe additionally designated Class A (2014).[7] |
| Brazil | Controlled | 25N-NBOMe explicitly listed as a controlled substance (February 2014).[7] |
| Canada | Schedule III | Covered under "2C-phenethylamines and their salts, derivatives, isomers" since October 2016.[7] |
| Russia | Controlled | NBOMe series controlled since October 2011.[7] |
| Sweden | Controlled | Added to controlled substances list August 2013.[7] |
| Australia | Schedule 9 (varies by state) | 25I-NBOMe is nationally prohibited; state-level schedules vary for other analogs. |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current status in the applicable jurisdiction before making any decisions.
references
- [1] ^abcEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. — Biochemical Pharmacology doi:10.1016/j.bcp.2018.09.024
- [2]
- [3]
- [4] ^abcdGee P, Schep LJ, Jensen BP, Moore G, Barrington S (2016) Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases. — Clinical Toxicology doi:10.3109/15563650.2015.1115056
- [5]
- [6]